Humacyte GAAP EPS of $0.28 beats by $0.47, revenue of $0.52M misses by $0.24M
Source: SeekingAlpha
2025-05-13 07:33:04 ET
More on Humacyte
- Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript
- Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel
- Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)
- Humacyte Q1 2025 Earnings Preview
- Humacyte down following quarterly results, hits record low
Read the full article on Seeking Alpha
For further details see:
Humacyte GAAP EPS of $0.28 beats by $0.47, revenue of $0.52M misses by $0.24M
Humacyte Inc.
NASDAQ: HUMA
HUMA Trading
0.0% G/L:
$1.165 Last:
1,302,350 Volume:
$1.15 Open:
HUMA Latest News
February 18, 2026 08:00:00 am
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
February 09, 2026 08:00:00 am
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
HUMA Stock Data
$220,166,898
198,988,939
0.6%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
